Search

Your search keyword '"López-Aldeguer J"' showing total 16 results
Start Over Author "López-Aldeguer J" Search Limiters Peer Reviewed
16 results on '"López-Aldeguer J"'

2. HIV-2 viral tropism influences CD4+ T cell count regardless of viral load

Author

Treviño, Ana, Soriano, Vicente, Poveda, Eva, Parra, Patricia, Cabezas, Teresa, Caballero, Estrella, Roc, Lourdes, Rodríguez, Carmen, Eiros, Jose M., Lopez, Mariola, De Mendoza, Carmen, Rodríguez, C., del Romero, J., Tuset, C., Marcaida, G., Ocete, M. D., Tuset, T., Caballero, E., Molina, I., Aguilera, A., Rodríguez-Calviño, J. J., Navarro, D., Regueiro, B., Benito, R., Gil, J., Borrás, M., Ortiz de Lejarazu, R., Eiros, J. M., Manzardo, C., Miró, J. M., García, J., Paz, I., Calderón, E., Leal, M., Vallejo, A., Abad, M., Dronda, F., Moreno, S., Escudero, D., Trigo, M., Diz, J., Álvarez, P., Cortizo, S., García-Campello, M., Rodríguez-Iglesias, M., Hernández-Betancor, A., Martín, A. M., Ramos, J. M., Gutiérrez, F., Rodríguez, J. C., Gómez-Hernando, C., Guelar, A., Cilla, G., Pérez-Trallero, E., López-Aldeguer, J., Sola, J., Fernández-Pereira, L., Niubó, J., Hernández, M., López-Lirola, A. M., Gómez-Sirvent, J. L., Force, L., Cifuentes, C., Pérez, S., Morano, L., Raya, C., González-Praetorius, A., Pérez, J. L., Peñaranda, M., Mena, A., Montejo, J. M., Roc, L., Martinez-Sapiña, A., Viciana, I., Cabezas, T., Lozano, A., Fernández, J. M., García Bermejo, I., Gaspar, G., García, R., Górgolas, M., Miralles, P., Aldamiz, T., García, F., Suárez, A., Treviño, A., Parra, P., de Mendoza, C., and Soriano, V.

Published
2014
Full Text
View/download PDF

3. Resistance to the most recent protease and non-nucleoside reverse transcriptase inhibitors across HIV-1 non-B subtypes

Author

Anta, Lourdes, Blanco, José L., Llibre, Josep M., García, Federico, Pérez-Elías, María J., Aguilera, Antonio, Pérez-Romero, Pilar, Caballero, Estrella, Vidal, Carmen, Cañizares, Angelina, Gutiérrez, Félix, Dalmau, David, Iribarren, José A., Soriano, Vicente, de Mendoza, Carmen, Iribarren, JA, Blanco, JL, Gatell, JM, Caballero, E, Ribera, E, Llibre, JM, Martínez-Picado, J, Clotet, B, Jaén, A, Dalmau, D, Peraire, J, Vidal, F, Vidal, C, Riera, M, Córdoba, J, López-Aldeguer, J, Galindo, MJ, Robledano, C, Gutiérrez, F, Álvarez, M, Chueca, N, García, F, Viciana, I, Santos, J, Pérez-Romero, P, Leal, M, Parra, M, Palomares, JC, Pineda, JA, Fernández-Cuenca, F, Rodríguez, C, del Romero, J, Menéndez-Arias, L, Pérez-Elías, MJ, Gutiérrez, C, Moreno, S, Pérez-Olmeda, M, Alcamí, J, Cañizares, A, Pedreira, J, Miralles, C, Ocampo, A, Morano, L, Rodríguez-Calviño, JJ, Aguilera, A, Gómez-Sirvent, JL, Anta, L, Poveda, E, Soriano, V, and de Mendoza, C

Published
2013
Full Text
View/download PDF

4. Effect of accompanying antiretroviral drugs on virological response to pegylated interferon and ribavirin in patients co-infected with HIV and hepatitis C virus

Author

Berenguer, Juan, von Wichmann, Miguel A., Quereda, Carmen, Miralles, Pilar, Mallolas, Josép, López-Aldeguer, José, Álvarez-Pellicer, Julio, De Miguel, Julio, Crespo, Manel, Guardiola, Josep M., Tellez, María J., Galindo, María J., Arponen, Sari, Barquilla, Elena, Bellón, José M., González-García, Juan, Miralles, P., Cosín, J., López, J. C., Padilla, B., Sánchez Conde, M., Bellón, J. M., Gutiérrez, I., Ramírez, M., Carretero, S., Aldamiz-Echevarría, T., Tejerina, F., Berenguer, J., Alvarez-Pellicer, J., Rodríguez, E., Arribas, J. R., Montes, M. L., Bernardino, I., Pascual, J. F., Zamora, F., Peña, J. M., Arnalich, F., González-García, J., Bustinduy, M. J., Iribarren, J. A., Rodríguez-Arrondo, F., Von-Wichmann, M. A., Blanes, M., Cuellar, S., Lacruz, J., Montero, M., Salavert, M., López-Aldeguer, J., Callau, P., Miró, J. M., Gatell, J. M., Mallolas, J., Ferrer, A., Galindo, M. J., Van den Eynde, E., Pérez, M., Ribera, E., Crespo, M., Vergas, J., Téllez, M. J., Casado, J. L., Dronda, F., Moreno, A., Pérez-Elías, M. J., Sanfrutos, M. A., Moreno, S., Quereda, C., Jou, A., Tural, C., Arranz, A., Casas, E., de Miguel, J., Schroeder, S., Sanz, J., Condés, E., Barros, C., Sanz, J., Santos, I., Hernando, A., Rodríguez, V., Rubio, R., Pulido, F., Domingo, P., Guardiola, J. M., Ortiz, L., Ortega, E., Torres, Leganés: R., Cervero, M., Jusdado, J. J., Montes, M. L., Pérez, G., Gaspar, G., Barquilla, E., Mahillo, B., Moyano, B., Cotarelo, M., Aznar, E., and Esteban, H.

Published
2011
Full Text
View/download PDF

5. Drug resistance mutations in patients infected with HIV-2 living in Spain

Author

Treviño, Ana, de Mendoza, Carmen, Caballero, Estrella, Rodríguez, Carmen, Parra, Patricia, Benito, Rafael, Cabezas, Teresa, Roc, Lourdes, Aguilera, Antonio, Soriano, Vincent, Rodríguez, C., del Romero, J., Tuset, C., Marcaida, G., Tuset, T., Caballero, E., Molina, I., Aguilera, A., Rodríguez-Calviño, J. J., Cortizo, S., Regueiro, B., Benito, R., Borrás, M., Ortiz de Lejarazu, R., Eiros, J. M., Miró, J. M., Lopez-Dieguez, M., Gutiérrez, M. M., Pumarola, T., García, J., Paz, I., Calderón, E., Medrano, F. J., Leal, M., Capote, F., Vallejo, A., Dronda, F., Moreno, S., Escudero, D., Pujol, E., Trigo, M., Diz, J., Álvarez, P., García-Campello, M., Rodríguez-Iglesias, M., Martín, A.M., Hernandez-Betancor, A., Ramos, J. M., Rodríguez, J. C., Gutiérrez, F., Gómez-Hernando, C., Guelar, A., Cilla, G., Pérez-Trallero, E., López-Aldeguer, J., Sola, J., Fernández-Pereira, L., Niubó, J., Veloso, S., Torres, A., López Lirola, A. M., Gómez Sirvent, J. L., Force, L., Cifuentes, C., García, J., Pérez, S., Raya, C., González-Praetorius, A., Mena, A., Pérez, J. L., Peñaranda, M., Montejo, J. M., Gutiérrez, M., Domingo, P., Roc, L., Martinez Sapiña, A., Viciana, I., Cabezas, T., Lozano, A., Fernandez, J. M., García, I., Gaspar, G., García, R., Gorgolas, M., Treviño, A., Parra, P., de Mendoza, C., and Soriano, V.

Published
2011
Full Text
View/download PDF

10. Pegylated interferon {alpha}2a plus ribavirin versus pegylated interferon {alpha}2b plus ribavirin for the treatment of chronic hepatitis C in HIV-infected patients.

Author

Berenguer J, GonzA¡lez-GarcA a J, LA(3)pez-Aldeguer J, Von-Wichmann MA, Quereda C, Hernando A, Sanz J, Tural C, Ortega E, Mallolas J, Santos I, Miralles P, Montes ML, BellA(3)n JM, Esteban H, Berenguer, J, González-García, J, López-Aldeguer, J, Von-Wichmann, M A, and Quereda, C

Abstract

Objectives: The two currently available types of pegylated interferon (peg-IFN) used to treat hepatitis C have different pharmacokinetic properties. It is unclear how these differences affect response to therapy. We compared the effectiveness and safety of peg-IFN-alpha2a and peg-IFN-alpha2b, both with ribavirin, against chronic hepatitis C virus (HCV) infection in HIV-infected patients.Methods: From the GESIDA HIV/HCV cohort, we analysed patients treated with peg-IFN-alpha2a (n = 315) or peg-IFN-alpha2b (n = 242). The primary endpoint was a sustained virological response (SVR).Results: Both groups were well matched in baseline characteristics except for a higher frequency of injection drug users in the peg-IFN-alpha2b group than in the peg-IFN-alpha2a group (85% versus 76%; P = 0.01) and a higher frequency of bridging fibrosis and cirrhosis (F3-F4) in the peg-IFN-alpha2b group than in the peg-IFN-alpha2a group (42% versus 33%; P = 0.04). End-of-treatment response was significantly lower among patients treated with peg-IFN-alpha2b [40% versus 52%; odds ratio (OR), 1.63; 95% confidence interval (95% CI), 1.16-2.29; P < 0.01]. However, no significant differences were found in SVR between patients treated with peg-IFN-alpha2b and those treated with peg-IFN-alpha2a (31% versus 33%; OR, 1.09; 95% CI, 0.75-1.59; P = 0.655). Therapy was interrupted due to adverse events in 33 (14%) patients treated with peg-IFN-alpha2b and 47 (15%) patients treated with peg-IFN-alpha2a.Conclusions: No differences in effectiveness and safety were found between peg-IFN-alpha2b and peg-IFN-alpha2a for the treatment of chronic HCV infection in HIV-infected patients. [ABSTRACT FROM AUTHOR]

Published
2009
Full Text
View/download PDF

13. Authors' reply.

Author

Garcia-Bustos, V, Calabuig, E, López-Aldeguer, J, and Moral Moral, P

Subjects
CHAGAS' disease, AUTOANTIBODIES, MUSCULOSKELETAL system diseases, TRYPANOSOMIASIS, VASCULITIS
Published
2020
Full Text
View/download PDF

14. Dyslipidaemia in HIV-infected women on antiretroviral therapy. Analysis of 922 patients from the Spanish VACH cohort

Author

Estrada Vicente, Geijo Paloma, Fuentes-Ferrer Manuel, Alcalde María, Rodrigo María, Galindo María, Muñoz Agustín, Domingo Pere, Ribera Esteve, Cosín Jaime, Viciana Pompeyo, Lozano Fernando, Terrón Alberto, Vergara Antonio, Teira Ramón, Muñoz-Sánchez Josefa, Roca Bernardino, Sánchez Trinitario, López-Aldeguer José, Deig Elisabeth, Vidal Francisco, Pedrol Enric, Castaño-Carracedo Manuel, Puig Teresa, Garrido Myriam, and Suárez-Lozano Ignacio

Subjects
Gynecology and obstetrics, RG1-991, Public aspects of medicine, RA1-1270
Abstract

Abstract Background Information concerning lipid disturbances in HIV-infected women on antiretroviral therapy (ART) is scarce. The objective of the study is to describe the lipid profile in a large cohort of HIV-infected women on contemporary ART and analyse differences between regimes and patient's characteristics. Methods Observational, multicentre, cross-sectional study from the Spanish VACH Cohort. 922 women on stable ART without lipid-lowering treatment were included. Results Median age was 42 years, median CD4 lymphocyte count was 544 cells/mm3, and 85.6% presented undetectable HIV-1 viral load. Median total cholesterol (TC) was 189 mg/dL (interquartile range, IQR, 165-221), HDL cholesterol 53 mg/dL (IQR, 44-64), LDL cholesterol 108 mg/dL (IQR, 86-134), and triglycerides 116 mg/dL (IQR, 85-163). Mean accumulated time on ART was 116 months; 47.4% were on NNRTI-based regimes, 44.7% on PI, and 6.7% on only-NRTI therapy. 43.8% were also hepatitis C (HCV) coinfected. Patients on PI treatment presented higher TC/HDL ratio than those on NNRTI (p < 0.001). Significantly higher HDL values were observed in NNRTI-treated patients. HCV-coinfected patients presented lower TC/HDL ratio than the non HCV-coinfected. In multivariate analysis, factors independently associated with TC/HDL ratio were age, triglyceride levels and HCV co-infection. PI treatment presented a non-significant association with higher TC/HDL ratio. Conclusions In HIV-infected women, the NNRTI-based ART is associated with a better lipid profile than the PI-based. Factors unrelated to ART selection may also exert an independent, significant influence on lipids; in particular, age, and triglyceride levels are associated with an increased TC/HDL ratio while HCV co-infection is associated with a reduced TC/HDL ratio.

Published
2011
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results